Decision Support in New York

Click Therapeutics is a New York-based digital therapeutics company founded in 2012 that develops and commercializes prescription software medical treatments for psychiatry, neurology, oncology, immunology, and cardiometabolic diseases. The company combines neuroscience with software engineering to create evidence-based digital treatments delivered via mobile platforms and prescribed by physicians. Click's core platform approach includes Prescription Digital Therapeutics (PDTs) and Software-Enhanced Drugs™ (Click SE™), which combine therapeutic software with pharmaceutical agents to enhance clinical outcomes. The company employs advanced AI and adaptive data science technologies, including its proprietary Clickometrics® platform, to personalize patient experiences and optimize treatment efficacy. Key FDA-cleared and investigational programs include CT-152 (Rejoyn™) for major depressive disorder, CT-132 for episodic migraine, and CT-155 for schizophrenia negative symptoms, supported by peer-reviewed clinical evidence and partnerships with major pharmaceutical companies including Otsuka Pharmaceutical and Boehringer Ingelheim.

CareTech Human manufactures FDA-registered, sensor-enabled medical devices for urology and remote patient monitoring. The company's flagship product simplifies uroflowmetry procedures through user-friendly technology integrated with automated symptom severity scoring and AI-powered data processing. The system enables objective health assessment with real-time patient compliance tracking, generating clinical-grade data suitable for both hospital and home use. CareTech's solution supports evidence-based clinical decision-making by delivering precise, actionable metrics while facilitating reimbursement through recognized remote monitoring codes. The platform prioritizes health data security and privacy, with clinical trial-ready technology designed for seamless integration into existing hospital workflows and urology practices.

Medidata is a leading cloud-based clinical trial management platform owned by Dassault Systèmes. The company provides an integrated software suite that connects patient, data, and study experiences across the entire clinical research lifecycle. The platform leverages AI and automation to streamline clinical trial operations, including patient engagement, electronic data capture, data management, regulatory submissions, and study oversight. Medidata's solutions serve pharmaceutical sponsors, contract research organizations (CROs), and clinical research sites globally. The platform has been used in over 100,000 clinical trials and processes billions of data points annually. Key capabilities include AI-driven study design and build automation, clinical data management with advanced analytics, real-time data quality monitoring, and patient experience tools designed to reduce burden and improve enrollment and retention. The company is trusted by major life sciences organizations and has achieved regulatory recognition, including FDA approval for novel drug submissions. Medidata operates as a Software-as-a-Service (SaaS) provider with a focus on accelerating clinical trial timelines, reducing costs, and improving data integrity. The platform integrates with existing clinical trial ecosystems and supports multi-study, multi-therapeutic area deployments.

GrayMatters Health develops Prism, an interventional psychiatry software platform that leverages fMRI-informed digital biomarkers and EEG neurofeedback to deliver personalized psychiatric care. The company's core technology uses real-time brain activity monitoring via EEG sensors to help patients self-regulate neural patterns associated with mental health conditions. Prism offers clinically validated protocols for PTSD (utilizing amygdala-based biomarkers) and Major Depressive Disorder (targeting ventral striatum reward-system activity). The platform integrates into clinical workflows, allowing technicians to administer sessions under clinician supervision, optimizing operational efficiency. GrayMatters emphasizes evidence-based design with published clinical studies demonstrating efficacy in symptom reduction and improved patient outcomes. The company provides comprehensive support including onsite installation, staff training, and ongoing technical assistance. Prism represents a bridge between neuroscience research and accessible psychiatric practice, enabling clinicians to augment standard-of-care therapies with objective, brain-derived biomarker data. The technology is designed for clinic deployment with minimal storage footprint and seamless integration into existing treatment protocols.

Koios Medical is a healthcare technology company that develops FDA-cleared, CE-marked AI-powered software for ultrasound image analysis, focusing on early detection of breast and thyroid cancers. The company's proprietary SmartUltrasound® platform (Koios DS™) leverages deep learning algorithms trained on over 500,000 breast lesion ultrasound images to provide clinical decision support for radiologists and sonographers. The platform assists in detecting, classifying, and characterizing suspicious lesions, reducing missed cancers by approximately 10x while improving workflow efficiency. Koios Medical operates on an annual subscription model and partners with major OEMs including GE Healthcare and Philips for distribution across 101+ installation sites in 28 countries. The company's AI-driven approach enhances diagnostic accuracy and supports billable ultrasound procedures, enabling healthcare facilities to streamline cancer detection workflows.

Behavidence develops a patented mobile application that delivers scientifically validated daily mental health monitoring through digital phenotyping and machine learning. The platform measures mood, focus, worry, and stress by analyzing passive digital biomarkers derived from smartphone usage patterns without tracking message content, websites visited, or typing activity. The solution is designed for healthcare providers (psychiatrists, physicians), clinical trial sponsors, insurance companies, and individual users seeking objective, measurement-based mental health assessment. The app supports standardized psychiatric questionnaires including PHQ-9, GAD-7, and ASRS for structured clinical evaluation. Regulatory credentials include HIPAA compliance and CE marking. Data security employs AES-256 encryption with full user anonymization. The platform offers SDK integration for embedding into existing healthcare IT systems and remote monitoring capabilities to support early intervention strategies. Clinically validated research demonstrates the app's accuracy in detecting mental health deterioration and predicting adverse outcomes. Primary use cases include ongoing patient monitoring in clinical practice, real-time digital phenotype collection for trial efficacy endpoints, and insurance-based early intervention programs for cost reduction. The solution is available on iOS and Android platforms.

Spark Neuro is a digital health company specializing in dementia diagnosis and care optimization. The company addresses a critical clinical gap: nearly 50% of dementia cases in the United States go undiagnosed, with primary care physicians lacking sufficient time and neurological expertise to conduct thorough cognitive assessments. Spark Neuro's platform leverages clinical decision-support technology to enable earlier dementia detection, identification of high-risk patients, and streamlined care pathways. The solution targets health plans, health systems, and primary care networks. Spark Neuro works with major healthcare organizations including Mayo Clinic, Johns Hopkins Medicine, Humana, and the National Institutes of Health, indicating regulatory credibility and clinical validation. The platform reduces provider burden by supporting PCPs in cognitive screening and assessment workflows, helping close diagnostic gaps while improving patient outcomes through early intervention. The company's value proposition centers on lowering undiagnosed dementia rates, improving care coordination between primary care and neurology specialists, and reducing long-term costs associated with late-stage dementia management.

PainChek Ltd. develops PainChek®, a clinically validated AI-enabled digital medical device for pain assessment in aged care, home care, hospitals, and neonatal settings. The software uses AI-driven technology and visual assessment to identify pain in individuals who cannot reliably self-report, including those with moderate to severe dementia. PainChek® generates personalized pain profiles and delivers results in under three minutes. The platform integrates seamlessly with leading Care Management Systems (CMS) and includes PainChek® Analytics, a cloud-based data intelligence portal providing actionable insights on pain trends and clinical outcomes. The company has facilitated over 15.9 million clinical assessments across 1,900+ facilities worldwide. PainChek® holds FDA De Novo clearance in the United States, is TGA-registered in Australia, and is approved for use in New Zealand, Canada, Singapore, Malaysia, the United Kingdom, and the European Union. Clinical evidence demonstrates reduced inappropriate use of psychotropic medications, increased pain assessments in cognitively impaired residents, and improved quality of life. The application is available on iOS and Android platforms. PainChek® supports care facilities in digital transformation while maintaining compliance with regulatory standards across multiple jurisdictions.

TytoCare is an AI-powered remote physical examination platform that enables clinicians to conduct comprehensive diagnostic exams from any location—home or community site. The company's Smart Clinic solutions include FDA-cleared hardware (digital stethoscopes, examination cameras) and advanced diagnostic software that replicates in-person clinical assessments for heart, lungs, throat, ears, skin, abdomen, and vital signs (temperature, heart rate). TytoCare serves 240+ healthcare organizations, 1.6M+ patients, and 40K+ providers globally, with deep integrations across health systems, health plans, and Medicaid programs. The platform features FDA-cleared AI algorithms for detection of pulmonary abnormalities (wheeze, rhonchi, crackles) and clinical decision support. Two primary offerings: Home Smart Clinic for patient self-exams with remote clinician supervision, and Pro Smart Clinic for field-based clinician-conducted exams. Clinical evidence demonstrates 6X higher utilization versus traditional telehealth, 98% remote resolution rate, 8.5% total cost-of-care reduction, and 83 NPS score. Trusted by Corewell Health, Sanford Health, Clalit, Elevance, Presbyterian, and major U.S. health systems.

CEIBA Health Technologies is an AI-powered healthcare technology platform specializing in virtual clinical care and medical device connectivity solutions. The company delivers an integrated Enterprise Suite with four core capabilities: (1) IoMT Interoperability—featuring a plug-and-play IoMT Box with 1,000+ pre-installed device drivers supporting 20+ EHR integrations; (2) Continuous Monitoring—delivering real-time telemetry dashboards for patient monitors, ventilators, infusion pumps, blood gas analyzers, and EEG machines across ICU, med-surge, LTACH, and SNF settings; (3) Decision Support & Workflow—providing actionable clinical insights and operational dashboards; and (4) Virtual Clinical Care—a telehealth platform enabling multi-specialty consultations, remote rounding, and acute care at home. CEIBA's protocol-agnostic architecture supports HL7, FHIR, JSON, and XML with enterprise-grade security, encrypted data transfer, and full mobile functionality. The platform is designed for rapid deployment (days vs. months) and serves hospitals and health systems in the US and internationally.